Los Angeles County + University of Southern California Medical Center, Los Angeles; Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles.
Los Angeles County + University of Southern California Medical Center, Los Angeles; Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles.
Am J Med. 2022 Mar;135(3):369-379.e1. doi: 10.1016/j.amjmed.2021.10.007. Epub 2021 Oct 27.
We sought to determine if controlled, prospective clinical data validate the long-standing belief that intravenous (IV) antibiotic therapy is required for the full duration of treatment for 3 invasive bacterial infections: osteomyelitis, bacteremia, and infective endocarditis.
We performed a systematic review of published, prospective, controlled trials that compared IV-only to oral stepdown regimens in the treatment of these diseases. Using the PubMed database, we identified 7 relevant randomized controlled trials (RCTs) of osteomyelitis, 9 of bacteremia, 1 including both osteomyelitis and bacteremia, and 3 of endocarditis, as well as one quasi-experimental endocarditis study. Study results were synthesized via forest plots and funnel charts (for risk of study bias), using RevMan 5.4.1 and Meta-Essentials freeware, respectively.
The 21 studies demonstrated either no difference in clinical efficacy, or superiority of oral versus IV-only antimicrobial therapy, including for mortality; in no study was IV-only treatment superior in efficacy. The frequency of catheter-related adverse events and duration of inpatient hospitalization were both greater in IV-only groups.
Numerous prospective, controlled investigations demonstrate that oral antibiotics are at least as effective, safer, and lead to shorter hospitalizations than IV-only therapy; no contrary data were identified. Treatment guidelines should be modified to indicate that oral therapy is appropriate for reasonably selected patients with osteomyelitis, bacteremia, and endocarditis.
我们旨在确定是否有控制、前瞻性的临床数据证实了一个长期以来的观点,即静脉(IV)抗生素治疗需要持续整个治疗过程,适用于三种侵袭性细菌感染:骨髓炎、菌血症和感染性心内膜炎。
我们对已发表的前瞻性对照试验进行了系统回顾,这些试验比较了这些疾病的单纯静脉用药与口服降阶梯治疗方案。我们使用 PubMed 数据库,确定了 7 项关于骨髓炎的随机对照试验(RCT)、9 项菌血症、1 项包括骨髓炎和菌血症的 RCT 以及 3 项心内膜炎 RCT,以及 1 项准实验性心内膜炎研究。使用 RevMan 5.4.1 和 Meta-Essentials 免费软件,通过森林图和漏斗图(用于研究偏倚风险)对研究结果进行综合分析。
21 项研究表明,在临床疗效方面,无论是死亡率还是口服与单纯静脉抗生素治疗的优势,均无差异;在任何研究中,单纯静脉治疗的疗效均无优势。单纯静脉组的导管相关不良事件发生率和住院时间均较长。
大量前瞻性对照研究表明,口服抗生素至少与单纯静脉治疗同样有效、更安全,并能缩短住院时间;没有发现相反的数据。治疗指南应加以修改,以表明口服治疗适用于合理选择的骨髓炎、菌血症和心内膜炎患者。